Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics


Inhibikase Therapeutics Inc. (IKT): $0.66

-0.05 (-7.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IKT Stock Summary

  • With a market capitalization of $17,911,206, INHIBIKASE THERAPEUTICS INC has a greater market value than merely 5.81% of US stocks.
  • IKT's price/sales ratio is 289.74; that's higher than the P/S ratio of 98.74% of US stocks.
  • Revenue growth over the past 12 months for INHIBIKASE THERAPEUTICS INC comes in at -98.11%, a number that bests just 0.77% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IKT, based on their financial statements, market capitalization, and price volatility, are SABS, NVEC, VCNX, BGRY, and DRRX.
  • IKT's SEC filings can be seen here. And to visit INHIBIKASE THERAPEUTICS INC's official web site, go to www.inhibikase.com.

IKT Valuation Summary

  • In comparison to the median Healthcare stock, IKT's price/earnings ratio is 103.96% lower, now standing at -0.9.
  • IKT's price/sales ratio has moved up 192.7 over the prior 25 months.

Below are key valuation metrics over time for IKT.

Stock Date P/S P/B P/E EV/EBIT
IKT 2023-01-20 277.4 0.7 -0.9 -0.6
IKT 2023-01-19 266.1 0.7 -0.9 -0.6
IKT 2023-01-18 266.1 0.7 -0.9 -0.6
IKT 2023-01-17 256.5 0.6 -0.8 -0.6
IKT 2023-01-13 243.5 0.6 -0.8 -0.5
IKT 2023-01-12 259.7 0.6 -0.9 -0.6

IKT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IKT has a Quality Grade of C, ranking ahead of 43.42% of graded US stocks.
  • IKT's asset turnover comes in at 0.094 -- ranking 267th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows IKT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.094 1 0.758

IKT Price Target

For more insight on analysts targets of IKT, see our IKT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.5 (Moderate Buy)

IKT Stock Price Chart Interactive Chart >

Price chart for IKT

IKT Price/Volume Stats

Current price $0.66 52-week high $1.52
Prev. close $0.71 52-week low $0.44
Day low $0.65 Volume 419,600
Day high $0.74 Avg. volume 601,683
50-day MA $0.60 Dividend yield N/A
200-day MA $0.80 Market Cap 16.60M

Inhibikase Therapeutics Inc. (IKT) Company Bio


Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.


IKT Latest News Stream


Event/Time News Detail
Loading, please wait...

IKT Latest Social Stream


Loading social stream, please wait...

View Full IKT Social Stream

Latest IKT News From Around the Web

Below are the latest news stories about INHIBIKASE THERAPEUTICS INC that investors may wish to consider to help them evaluate IKT as an investment opportunity.

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the dosing of the first three subjects in its '501' bioequivalence study of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imati

Yahoo | December 12, 2022

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, announced that it has received the U.S. Food and Drug Administration's (FDA) clinical hold letter in regards to the Company's IkT-148009 programs in Parkinson's disease and Multiple System Atrophy.

Yahoo | December 7, 2022

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Piper Sandler 34th Annual Healthcare Conference being held on November 29 – December 1, 2022, in New Yo

Yahoo | November 22, 2022

JonesTrading Keeps Their Hold Rating on Inhibikase Therapeutics (IKT)

JonesTrading analyst Soumit Roy maintained a Hold rating on Inhibikase Therapeutics (IKT - Research Report) today. The company's shares closed today at $0.62.Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and Day One Biopharmaceuticals. According to TipRanks, Roy has an average return of 10.3% and a 35.16% success rate on recommended stocks. Inhibikase Therapeutics has an analyst consensus of Hold.See the top stocks recommended by analysts >>Based on Inhibikase Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.64 million. In comparison, last year the company had a GAAP net loss of $2.

Catie Powers on TipRanks | November 15, 2022

Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript

Inhibikase Therapeutics, Inc. (NASDAQ:NASDAQ:IKT) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Investor Relations Milton Werner –…

Seeking Alpha | November 15, 2022

Read More 'IKT' Stories Here

IKT Price Returns

1-mo 29.46%
3-mo -15.03%
6-mo -20.83%
1-year -47.20%
3-year N/A
5-year N/A
YTD 32.00%
2022 -65.99%
2021 -78.70%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6088 seconds.